MX2017001010A - Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same. - Google Patents
Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same.Info
- Publication number
- MX2017001010A MX2017001010A MX2017001010A MX2017001010A MX2017001010A MX 2017001010 A MX2017001010 A MX 2017001010A MX 2017001010 A MX2017001010 A MX 2017001010A MX 2017001010 A MX2017001010 A MX 2017001010A MX 2017001010 A MX2017001010 A MX 2017001010A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- cytoplasm
- relates
- present
- positioning
- Prior art date
Links
- 210000000805 cytoplasm Anatomy 0.000 title abstract 4
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 3
- 102000018358 immunoglobulin Human genes 0.000 title abstract 3
- 210000000170 cell membrane Anatomy 0.000 title abstract 2
- 230000000149 penetrating effect Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 3
- 230000000975 bioactive effect Effects 0.000 abstract 2
- 230000035515 penetration Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to a method for positioning, in a cytoplasm, an antibody having a complete immunoglobulin form, by means of active cell penetration. In addition, the present invention relates to a light chain variable region (VL) that induces the active penetration of a cell membrane of a living cell by an antibody having a complete immunoglobulin form and the positioning of the antibody in the cytoplasm, and an antibody comprising same. Also, the present invention relates to a bioactive molecule fused to the antibody. Also, the present invention relates to a composition for preventing, treating or diagnosing cancer, comprising the antibody or the bioactive molecule fused to same. The present invention also relates to a polynucleotide that codes the light chain variable region and the antibody. The present invention also relates to a method for preparing an antibody that is made to penetrate through to the inside of a cell and positioned in the cytoplasm.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140092673 | 2014-07-22 | ||
| KR20150013163 | 2015-07-21 | ||
| PCT/KR2015/007626 WO2016013870A1 (en) | 2014-07-22 | 2015-07-22 | Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017001010A true MX2017001010A (en) | 2018-03-08 |
Family
ID=62778633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001010A MX2017001010A (en) | 2014-07-22 | 2015-07-22 | Method for positioning, in cytoplasm, antibody having complete immunoglobulin form by penetrating antibody through cell membrane, and use for same. |
Country Status (1)
| Country | Link |
|---|---|
| MX (1) | MX2017001010A (en) |
-
2015
- 2015-07-22 MX MX2017001010A patent/MX2017001010A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| EA201990293A1 (en) | MULTI-SPECIFIC ANTIBODIES AGAINST CD40 AND CD137 | |
| SA517381703B1 (en) | Anti-C10orf54 Antibodies And Uses Thereof | |
| CO2017004516A2 (en) | Humanized anti-ox40 antibodies | |
| EA201891983A8 (en) | COMBINED THERAPY BY ANTIBODIES TO CD73 | |
| EA201790173A1 (en) | ANTIBODIES CONNECTING AXL | |
| PH12016501828A1 (en) | Anti-egfr antibodies and antibody drug conjugates | |
| JO3714B1 (en) | Antibody constructs for CD70 and CD3 | |
| TW201613979A (en) | Anti-LAG3 antibodies and antigen-binding fragments | |
| MX373280B (en) | ANTI-EGFRVIII ANTIBODIES AND THEIR USES. | |
| ECSP17034845A (en) | ANTIBODY CONJUGATES - DRUG | |
| PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
| EA201890305A1 (en) | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | |
| EA201790545A1 (en) | ANTIBODIES AND IMMUNOCONJUGATES AGAINST HER2 | |
| PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
| PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
| EA201690167A1 (en) | HUMANIZED OR CHEMICAL ANTIBODIES TO CD3 | |
| MX2016014862A (en) | Her3/her2 bispecific antibodies binding to the beta-hairpin of her3 and domain ii of her2. | |
| AR100944A1 (en) | INTERFERON ANTAGONIST ANTIBODIES a Y w | |
| MX2018006249A (en) | Novel anti-emr2 antibodies and methods of use. | |
| MX2023006415A (en) | ANTIBODIES, USES AND METHODS. | |
| EA201792612A1 (en) | 6-AMINOHINOLIN-3-CARBONITRILES AS COT MODULATORS | |
| EA201891527A1 (en) | COMPOSITIONS AND METHODS OF DETECTION AND TREATMENT OF CANCER ETHESIS | |
| MX2018007817A (en) | Novel anti-mmp16 antibodies and methods of use. | |
| EA201990978A1 (en) | ANTIBODIES AGAINST PD-1 |